Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement - Chortis, V; Taylor, A E; Schneider, P; Tomlinson, J W; Hughes, B A; O’Neil, D M; Libe, R; Allolio, B; Bertagna, X; Bertherat, J; Beuschlein, F; Fassnacht, M; Karavitaki, N; Mannelli, M; Mantero, F; Opocher, G; Porfiri, E; Quinkler, M; Sherlock, M; Terzolo, M; Nightingale, P; Shackleton, C H; Stewart, P M; Hahner, S; Arlt, W (J Clin Endo Metabol, 2013)